Mantle Cell Lymphoma
Latest News
Latest Videos
More News
Zanubrutinib induced an overall response rate of 83.5% in patients with relapsed/refractory mantle cell lymphoma, with many responses demonstrating durability, according to the results of a phase II trial.<br />
In an interview with <em>Targeted Oncology</em>, Jonathon B. Cohen, MD, discussed the evolving treatment landscape of MCL.
The FDA has granted approval to the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy, making it the first biosimilar approved by the FDA for the treatment of patients with NHL.
Using the VR-CAP regimen instead of R-CHOP significantly improved median overall survival in previously untreated newly diagnosed patients with mantle cell lymphoma who were not eligible for transplant, according to results from the long-term follow-up phase of a randomized, open-label, phase III trial.
According to Robert Dean, MD, BTK inhibitors and CAR T cells may fulfill an unmet need in patients with mantle cell lymphoma. Experts have been hard-pressed to find long-lasting treatments like these that have the potential to impact this patient population.
Jonathon B. Cohen, MD, discusses the biggest challenge in treating mantle cell lymphoma and how these challenges can be overcome.
During a presentation at the National Comprehensive Cancer Network 13th Annual Conference: Hematologic Malignancies Phillippe Armand, MD, PhD, discusses how novel agents could be used in the future either to postpone, permit, or even replace allogeneic stem cell transplantation.
A greater understanding of molecular pathogenesis in non-Hodgkin lymphoma has led to the identification of rational targets for novel small molecule inhibitors, according to Andrew D. Zelenetz, MD, PhD. Combinations of these therapies may also provide greater responses and the potential for therapy discontinuation.
Brentuximab vedotin (Adcetris) has been granted FDA approval for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma, based on findings from the phase III ECHELON-2 trial.
During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.
Based on findings from the phase III ECHELON-2 trial, brentuximab vedotin (Adcetris) has been submitted to the FDA for approval in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
Simon Rule, MD, PhD, discusses the treatment options available for younger, fit patients with MCL, including the watch-and-wait approach and BTK inhibitors. He also highlights several clinical trials supporting these strategies, as well as other ongoing trials aiming to advance the treatment landscape for the older patient population.
The treatment landscapes of Hodgkin lymphoma and mantle cell lymphoma have progressed to a more personalized therapeutic approach in clinical practice due to the introduction of the latest novel regimens, according to Chaitra S. Ujjani, MD.
Simon Rule, MD, PhD, shares his treatment considerations for select patients with mantle cell lymphoma.
With 2 CAR T-cell therapies now approved and more moving quickly through early-phase clinical trials, 4 healthcare experts reflected on the evolving field of CAR T-cell therapy, their understanding of its current and future applicability for patients, the process for administration and the challenges and obstacles that remain unaddressed during an Association of Community Cancer Centers interactive panel.<br />
Michael Wang, MD, discusses the latest options for patients with relapsed MCL, while also addressing some of the challenges with these agents.
David G. Maloney, MD, PhD, reviews the latest developments with CAR T-cell therapy in patients with non-Hodgkin lymphoma.
In a 16-0 vote, the FDA’s Oncologic Drugs Advisory Committee has recommended the approval of the rituximab biosimilar CT-P10 for 3 of the anti-CD20 monoclonal antibody’s non-Hodgkin lymphoma indications.
Guidelines from the International Lymphoma Radiation Oncology Group recommend the use of proton therapy in adults with mediastinal lymphomas and for young women. Specifically, clinicians should consider proton therapy in mediastinal disease that spans below the left main stem coronary artery and is near the front of, behind, or on the left side of the heart.
Patients with mantle cell lymphoma who were treated with the combination of lenalidomide (Revlimid) and rituximab (Rituxan) continued to have durable responses and manageable side effects at 5 years of follow-up.
A look back at all the FDA news that happened in the month of September 2018, including several new approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.
Patients with CD30-expressing peripheral T-cell lymphoma who were treated with the combination of brentuximab vedotin and frontline chemotherapy experienced a statistically significant improvement in progression-free and overall survival, according to topline results from the phase III ECHELON-2 trial.
Philip Bierman, MD, discusses the current landscape of central nervous system involvement in aggressive lymphoma and the research that still needs to be conducted.
Antibody–drug conjugate therapies are making a larger impact on the treatment paradigm for patients with lymphomas, especially following promising data for brentuximab vedotin and inotuzumab ozogamicin.
Pontchartrain Cancer Center was founded in 2005 to serve an area of Louisiana that lacked the necessary resources for cancer care. This community cancer center, with 2 locations in Southeast Louisiana, accommodates any patient to walk through its doors, filling a major unmet need for the community in this rural area.